Drug Watch

Latest News

FDA Approves Arcutis’ Roflumilast Foam for Plaque Psoriasis
FDA Approves Arcutis’ Roflumilast Foam for Plaque Psoriasis

May 22nd 2025

FDA approves Arcutis' roflumilast foam, a groundbreaking treatment for plaque psoriasis, offering a steroid-free, effective solution for patients aged 12 and older.

Quoin Receives FDA Clearance for Second Netherton Trial
Quoin Receives FDA Clearance for Second Netherton Trial

May 22nd 2025

AC-201 Shows Strong Phase 2 Results in Psoriasis Trial
AC-201 Shows Strong Phase 2 Results in Psoriasis Trial

May 21st 2025

Expert Insights Highlight Novel ITK Inhibition With Soquelitinib for AD
Expert Insights Highlight Novel ITK Inhibition With Soquelitinib for AD

May 19th 2025

Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis
Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis

May 15th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.